PDX Portal

Model Details

Patient Information for Model: BCM-15100

Model Contact

Model: BCM-15100
Model Contact: Michael Lewis
Institution: BCM Breast PDX Program
Email: mtlewis@bcm.edu

Patient Information

Clinical Timeline

Color Keys:

Positive

Negative

N/A

Clinical Information at Collection

Clinical Biomarkers/Mutations at Collection

Pathology Information at Collection

Model Information for Model: BCM-15100

Model Details - Initial Implantation of Patient Tissue

Biomarkers & Mutations

Model Details - Acceptable Conditions for Passaging

Mutations (Cancer Gene Census List)

GeneFilter by Gene	ChrFilter by Chr	Start	End	Ref	Alt	cDNA Change	Codon Change	Protein Change	TVAF	Gene Mutation Freq.	Site Mutation Freq.	Most Severe Effect	All Effects	Mutation Impact	Transcript ID	ClinVar Clinical Significance	COSMIC ID	gnomAD Non-Cancer AF	dbSNP ID	Gene Mutation Freq.	Site Mutation Freq.	Transcript ID	ClinVar Clinical Significance	COSMIC ID	dbSNP ID
ABL1	chr9	130884102	130884105	CAAG	C	c.1826_1828del	AAG/-	p.K609del	0.109	55	42	In-frame Deletion	In-frame Deletion	MODERATE	ENST00000318560.6		COSV59324524		rs201725154	55	42	ENST00000318560.6		COSV59324524	rs201725154
AFDN	chr6	167966011	167966014	TGAG	T	c.5091_5093del	GAG/-	p.E1697del	0.06	50	35	In-frame Deletion	In-frame Deletion	MODERATE	ENST00000366806.6		COSV60040388		.	50	35	ENST00000366806.6		COSV60040388	.
AKAP9	chr7	92001306	92001306	G	T	c.1389G>T	atG/atT	p.M463I	0.948	115	73	Missense Variant	Missense Variant	MODERATE	ENST00000356239.8	Benign	COSV62345589	0.376835000000	rs6964587	115	73	ENST00000356239.8	Benign	COSV62345589	rs6964587
AKAP9	chr7	92085597	92085597	C	T	c.8935C>T	Cct/Tct	p.P2979S	0.962	115	115	Missense Variant	Missense Variant	MODERATE	ENST00000356239.8	Benign/Likely_benign	COSV104663065	0.996325000000	rs1063242	115	115	ENST00000356239.8	Benign/Likely_benign	COSV104663065	rs1063242
AKAP9	chr7	92083384	92083384	A	G	c.8375A>G	aAt/aGt	p.N2792S	0.98	115	62	Missense Variant	Missense Variant	MODERATE	ENST00000356239.8	Benign/Likely_benign	COSV62339152	0.357813000000	rs6960867	115	62	ENST00000356239.8	Benign/Likely_benign	COSV62339152	rs6960867
AKAP9	chr7	92022864	92022864	A	AAAC	c.4004_4006dup	aaa/aAACaa	p.K1335_L1336insQ	0.984	115	73	In-frame Insertion	In-frame Insertion	MODERATE	ENST00000356239.8		COSV62337888		rs10644111	115	73	ENST00000356239.8		COSV62337888	rs10644111
ALK	chr2	29193500	29193500	G	C	c.4587C>G	gaC/gaG	p.D1529E	0.522	115	80	Missense Variant	Missense Variant	MODERATE	ENST00000389048.8	Benign	COSV66569695	0.472160000000	rs1881421	115	80	ENST00000389048.8	Benign	COSV66569695	rs1881421
ALK	chr2	29193706	29193706	T	C	c.4381A>G	Atc/Gtc	p.I1461V	0.988	115	115	Missense Variant	Missense Variant	MODERATE	ENST00000389048.8	Benign	COSV101201052	0.997594000000	rs1670283	115	115	ENST00000389048.8	Benign	COSV101201052	rs1670283
APC	chr5	112841059	112841059	T	A	c.5465T>A	gTc/gAc	p.V1822D	0.459	100	100	Missense Variant	Missense Variant	MODERATE	ENST00000257430.9	Benign	COSV57321643	0.794920000000	rs459552	100	100	ENST00000257430.9	Benign	COSV57321643	rs459552
AR	chrX	67545316	67545316	T	TGCA	c.237_239dup	ctg/ctGCAg	p.Q80dup	0.29	101	14	In-frame Insertion	In-frame Insertion	MODERATE	ENST00000374690.9		COSV65952534		.	101	14	ENST00000374690.9		COSV65952534	.
AR	chrX	67545316	67545316	T	TGCAGCA	c.234_239dup	ctg/ctGCAGCAg	p.Q79_Q80dup	0.626	101	15	In-frame Insertion	In-frame Insertion	MODERATE	ENST00000374690.9		COSV65953707		.	101	15	ENST00000374690.9		COSV65953707	.
ARID1B	chr6	156778031	156778034	GTCC	G	c.370_372del	TCC/-	p.S124del	0.048	80	33	In-frame Deletion	In-frame Deletion	MODERATE	ENST00000636930.2		COSV105107929		.	80	33	ENST00000636930.2		COSV105107929	.
ARID1B	chr6	156778268	156778268	C	CCAGCAG	c.606_611dup	-/CAGCAG	p.Q213_Q214dup	0.833	80	4	In-frame Insertion	In-frame Insertion	MODERATE	ENST00000636930.2		COSV51647062		.	80	4	ENST00000636930.2		COSV51647062	.
ARID1B	chr6	156778268	156778268	C	CCAG	c.609_611dup	-/CAG	p.Q214dup	0.07	80	4	In-frame Insertion	In-frame Insertion	MODERATE	ENST00000636930.2		COSV51651299		.	80	4	ENST00000636930.2		COSV51651299	.
ATIC	chr2	215325297	215325297	C	G	c.347C>G	aCt/aGt	p.T116S	0.473	52	43	Missense Variant	Missense Variant	MODERATE	ENST00000236959.14	Benign	COSV52691660	0.326476000000	rs2372536	52	43	ENST00000236959.14	Benign	COSV52691660	rs2372536

CNV

PDX Validation

In order to validate the identity of Baylor College of Medicine patient-derived xenograft (PDX) models, short tandem repeat (STR) testing is performed at the Cytogenetics and Cell Authentication core facility at MDACC. STR testing is performed on tissue from the initial tumor grown in the mouse (transplant generation 1 - TG1) and from a patient sample when possible. Thereafter, STR testing is performed every five transplant generations (TG5, TG10, TG15, and TG20). In the case that a PDX model is transplanted from viably frozen tissue to restart the model, the PDX Core will test the first outgrowth to confirm identity and every five transplant generations thereafter. In addition to STR, we assess clinical biomarkers and histology every 5th transplant generation. Finally, RNAseq gene expression profiles are evaluated periodically to ensure consistency with previous results and to evaluate phenotypic drift. If a significant change in PDX biology is noted, we identify the last known stable stock and re-start the model.

Histology Information for Model: BCM-15100

There are no histology images for this model.

Metastasis Information for Model: BCM-15100

Patient

PDX

Abdomen

Adrenal gland

Bone

Bones

Brain

CTC

Chest

Chest wall

Contralateral Breast

Dura

Fallopian Tubes

Head

Kidney

Liver

Lung

Lymph node

Lymph nodes

Neck

Ovary

Pancreas

Pericardium

Peritoneal cavity

Peritoneum

Pleura

Pleural effusion

Shoulder

Skin

Spine

Spleen

Thoracic Spine

Thymus

Patient Treatment Information for Model: BCM-15100

Event Id	Treatment	Treatment Setting	Age at Start	Age at End	Duration	Clinical Response	Pathologic Response	Reason Stopped
15	Cyclophosphamide,Docetaxel	Adjuvant	38.08	38.34	95 days	Not Reported	Not Applicable	Treatment Completed
20	Radiation Therapy	Adjuvant	38.34	38.42	29 days	Not Reported	Not Applicable	Treatment Completed
25	Tamoxifen	Adjuvant	38.5	39.64	416 days	Progressive Disease	Not Applicable	Disease Progression
35	Leuprolide,Denosumab	Metastatic	39.64	39.72	29 days	Disease Progression	Not Applicable	Disease Progression
40	Oophorectomy	Prophylactic	39.7	39.7	1	Not Reported	Not Applicable	Other
45	Letrozole,Denosumab	Metastatic	39.72	42.09	865 days	Not Reported	Not Applicable	Side Effects
55	Tamoxifen	Metastatic	42.09	42.1	4 days	Disease Progression	Not Applicable	Disease Progression
65	Denosumab,Paclitaxel	Metastatic	42.14	42.38	88 days	Not Reported	Not Applicable	Unknown
70	Fulvestrant,Denosumab	Metastatic	42.4	43.26	314 days	Disease Progression	Not Applicable	Disease Progression
85	Capecitabine,Denosumab	Metastatic	43.27	44.0	266 days	Disease Progression	Not Applicable	Disease Progression
100	Fulvestrant,Palbociclib	Metastatic	44.09	44.63	197 days	Disease Progression	Not Applicable	Disease Progression
120	Doxorubicin	Metastatic	44.74	45.34	219 days	Disease Progression	Not Applicable	Disease Progression
130	Eribulin	Metastatic	45.45	45.67	80 days	Disease Progression	Not Applicable	Disease Progression
150	Carboplatin	Metastatic	45.67	45.7	11 days	Not Reported	Not Applicable	Side Effects
155	Stereotactic radiosurgery	Metastatic	45.78	45.78	1	Not Reported	Not Applicable	Unknown